Clozapine and the Mandatory Monitoring System

L. S. Lehmann, L. Rodriguez, Joseph H. Friedman, Carol A. Bernstein, Robert Eilers

Research output: Contribution to journalLetter

3 Scopus citations

Abstract

To the Editor: Dr. Salzman, in his Sounding Board article (Sept. 20 issue),1 has identified key aspects of what he generously characterizes as an “unusual” marketing strategy employed by Sandoz in tying the availability of the new antipsychotic agent clozapine (Clozaril) to its own monitoring and distribution system (the Clozaril Patient Monitoring System, or CPMS). This logistically cumbersome system accounts for some $7,000 of the exorbitant $9,000 annual cost per patient for Clozaril. The Department of Veterans Affairs (VA) has developed an alternative monitoring system with an automatic computerized lockout feature that prevents the dispensing of clozapine to a patient.

Original languageEnglish (US)
Pages (from-to)490-491
Number of pages2
JournalNew England Journal of Medicine
Volume324
Issue number7
DOIs
StatePublished - Feb 14 1991
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Clozapine and the Mandatory Monitoring System'. Together they form a unique fingerprint.

  • Cite this